Choosing PEZA favors export-focused operations with zone controls; BOI suits domestic or mixed markets, offering broader site flexibility and simplified compliance, influencing incentives, operations, and supply chain setup.

Choosing Between PEZA and BOI

Deciding between the Philippine Economic Zone Authority (PEZA) and the Board of Investments (BOI) hinges on whether a business focuses on export compliance or domestic market access. PEZA is tailored for export-driven operations, offering benefits for companies that generate approximately 70% or more from exports. Conversely, BOI caters to domestic market activities, including local distribution, retail, wholesale, and e-commerce, suitable for businesses with a primarily internal sales focus. This choice impacts revenue eligibility, tax incentives, and supply chain design.

Operational and Location Considerations

PEZA requires physical presence within designated economic zones, providing customs supervision and duty facilitation but limiting operational flexibility. BOI allows companies to set up anywhere nationwide, such as Metro Manila, Cebu, or Davao, enhancing distribution efficiency. While BOI offers greater location freedom, it lacks automatic access to bonded systems available within PEZA zones, influencing logistics and import/export processes.

Eligibility, Compliance, and Transition

PEZA registration demands continuous export performance monitoring within a controlled environment, favoring companies committed to export growth. BOI emphasizes performance-based reporting aligned with registered activities, offering more operational flexibility but requiring diligent compliance. Transitioning between PEZA and BOI involves restructuring, often costly and disruptive, underscoring the importance of choosing the appropriate registration pathway during the initial setup.

---

---

Read the original article : PEZA vs BOI in the Philippines: Which Incentive Structure Fits Your Manufacturing or Logistics Model?

Other People are Reading

The 20 wealthiest Asian clans have a combined net worth of $647 billion. Despite growing concerns over an AI bubble, these powerful families continue to maintain substantial financial influence. Their extensive wealth underscores their significant role in the region’s economic landscape, highlighting both their stability and the ongoing impact of technological advancements on wealth accumulation.

---

Artificial Intelligence (AI) is transforming Asia’s wealth landscape by empowering its richest families with unprecedented technological advantages. These families are leveraging AI-driven data analysis and automation to optimize their investments, streamline operations, and make more informed decisions. For instance, many business dynasties in China and India utilize AI to enhance supply chain efficiency, predict market trends, and identify lucrative opportunities faster than ever before. This technological edge allows them to maintain and grow their wealth in an increasingly competitive environment.

Moreover, AI-enabled insights are revolutionizing sectors like finance, real estate, and manufacturing, where Asia’s elite families have vested interests. AI algorithms assist in uncovering hidden market patterns, enabling strategic acquisitions and asset management. These innovations not only boost profitability but also secure long-term dominance within their respective industries. As AI continues to evolve, it will likely further widen the wealth gap, making Asia’s richest families even more powerful.

In conclusion, AI’s influence is amplifying the fortunes of Asia’s elite, providing them with tools for more aggressive expansion and wealth preservation. By embracing cutting-edge technology, these families are cementing their status in the global hierarchy of wealth. As AI developments accelerate, it is clear that Asia’s wealthiest are set to benefit even more, profoundly shaping economic power dynamics across the continent.

source

Other People are Reading

Günther Ofner
CFO & Member of the Management Board

You already saw our main results, and we had a moderate revenue and earnings increase in Q1 ’26. Revenue up 6.1%, EBITDA up 8.2%, and group net profit up 5.3%. We saw overall a positive traffic development in the group with 5.3% plus, especially resulting in strong growth in Malta and Košice. In Vienna, it was 1.6%, including Air India transit passengers in the refueling stops. We saw a positive non-aviation performance, higher de-icing revenues and no winter incentive compared to 2025, which positively contributed to our results. We successfully implemented and are still in the process of implementation of our cost saving and efficiency measures. And I hope we can realize all the plans throughout the year.

Clearly, the Middle East conflict is increasing uncertainty for the coming months. And hopefully, these negative effects will stop very soon. What might be of more importance midterm, at least are the effects of higher fuel costs, which might result in some airline capacity adjustments and also higher ticket prices by many of the carriers to offset these additional costs. Despite all that uncertainty, we can confirm our passenger and financial outlook for 2026 so far. And I hope that the rest of the year will not prove us wrong.

If we move on, you see that our financial results are positive, also reduced by half due to the fact that

India’s foreign direct investment (FDI) inflows increased 17.2% year-on-year to $94.5 billion in 2025-26, aided by overseas investor interest despite global macroeconomic uncertainty and volatile capital flows, according to the Reserve Bank of India‘s latest monthly bulletin.

Gross FDI inflows stood at $94.5 billion in 2025-26 compared with $80.6 billion in the previous year, while net FDI inflows increased sharply to $7.7 billion from $1 billion a year ago.

“On the capital account, gross FDI has been encouraging,” the RBI said, adding that inflows are expected to remain robust amid a recent wave of greenfield investment announcements, particularly in the finance and technology sectors.

The central bank said that March marked the second consecutive month of positive net FDI inflows, despite moderation in gross inflows, aided by lower repatriation and outward FDI. Outward FDI also eased in March, with more than half of the investments directed towards Singapore, the UAE and the Netherlands.

Meanwhile, external commercial borrowings moderated to $43 billion in 2025-26 from $61.2 billion a year earlier, as Indian companies turned cautious on overseas borrowings amid elevated global interest rates and relatively attractive domestic funding conditions.
The RBI also flagged continued pressure from foreign portfolio investor (FPI) outflows. FPIs remained net sellers in April and May amid geopolitical tensions and uncertainty in West Asia, with cumulative outflows of about $10 billion so far in 2026-27, largely from equities.

By Jennifer Nash

Despite a rough start to the week, the S&P 500 rallied in the back half to post its eighth consecutive weekly gain, its longest streak since 2023. Ultimately rising 0.9%, the index is now inches away

Follow

Play Earnings CallPlay Earnings Call

Lyell Immunopharma, Inc. (LYEL) Stifel 2026 Targeted Oncology Virtual Forum May 20, 2026 4:00 PM EDT

Company Participants

Lynn Seely – Principal Executive Officer, President, CEO & Director

Advertisement

Conference Call Participants

Stephen Willey – Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Advertisement

Stephen Willey
Stifel, Nicolaus & Company, Incorporated, Research Division

All right. Good afternoon, everyone. I’m Stephen Willey, one of the senior biotech analysts here at Stifel. I’m very glad to have with us in the next session, Lynn Seely, who is the President and CEO of Lyell. Lynn, thanks for joining us. Always appreciate it. Any opening statements you want to make or a brief overview of the company you want to provide before we jump into Q&A?

Lynn Seely
Principal Executive Officer, President, CEO & Director

Advertisement

Sure. I’m happy to give an overview for those who may not be as familiar with Lyell maybe for the record, I should say I’ll be making some forward-looking statements here. So consult our website. But for those of you who don’t know Lyell Immunopharma, we are a cell therapy company, and we’re focused on next-generation cell therapies, both for patients with hematologic malignancies as well as for solid tumors. And we have 2 lead programs in the clinic, both for large markets one in large B-cell lymphoma, where we intend to displace the currently approved CD19 CARs, which have a $3 billion and growing marketplace. And then the second, very novel CAR for metastatic colorectal cancer. So I look forward to telling you about those. / And then I should also just make note of the fact that Lyell is a little bit unique in that we have our own manufacturing like facility where we can launch from that facility and get well into launch with our own manufacturing. So that puts control under our own destiny, which we really like.

This is the forum for daily political discussion on Seeking Alpha. A new version is published every market day.

Please don’t leave political comments on other articles or posts on the site.

The comments below are not regulated with the same rigor as the rest of the site, and this is an ‘enter at your own risk’ area as discussion can get very heated. If you can’t stand the heat… you know what they say…

More on Today’s Markets:

Moderation Guidelines:

We remove comments under the following categories:

• Personal attacks on another user account
• Anti-Vaxxer or covid related misinformation
• Stereotyping, prejudiced or racist language about individuals or the topic under discussion.
• Inciting violence messages, encouraging hate groups and political violence.

Regardless of which side of the political divide you find yourself, please be courteous and don’t direct abuse at other users.

For any issue with regards to comments please email us at : moderation@seekingalpha.com.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.